These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36142419)

  • 21. Independent effect of Aβ burden on cognitive impairment in patients with small subcortical infarction.
    Kang SH; Kang M; Han JH; Lee ES; Lee KJ; Chung SJ; Suh SI; Koh SB; Eo JS; Kim CK; Oh K
    Alzheimers Res Ther; 2023 Oct; 15(1):178. PubMed ID: 37838715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel imaging techniques in cerebral small vessel diseases and vascular cognitive impairment.
    Banerjee G; Wilson D; Jäger HR; Werring DJ
    Biochim Biophys Acta; 2016 May; 1862(5):926-38. PubMed ID: 26687324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Cerebrovascular Disease in Amyloid Deposition.
    Noh Y; Seo SW; Jeon S; Lee JM; Kim JS; Lee JH; Kim JH; Kim GH; Ye BS; Cho H; Kim HJ; Yoon CW; Choe YS; Lee KH; Weiner MW; Na DL
    J Alzheimers Dis; 2016 Oct; 54(3):1015-1026. PubMed ID: 27567803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease.
    Dang M; Chen Q; Zhao X; Chen K; Li X; Zhang J; Lu J; Ai L; Chen Y; Zhang Z
    Hum Brain Mapp; 2023 Feb; 44(2):327-340. PubMed ID: 36647262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
    Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
    Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET.
    Tsoy E; Strom A; Iaccarino L; Erlhoff SJ; Goode CA; Rodriguez AM; Rabinovici GD; Miller BL; Kramer JH; Rankin KP; La Joie R; Possin KL
    Alzheimers Res Ther; 2021 Feb; 13(1):36. PubMed ID: 33557905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.
    Chandra A; Valkimadi PE; Pagano G; Cousins O; Dervenoulas G; Politis M;
    Hum Brain Mapp; 2019 Dec; 40(18):5424-5442. PubMed ID: 31520513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer disease biomarkers are associated with body mass index.
    Vidoni ED; Townley RA; Honea RA; Burns JM;
    Neurology; 2011 Nov; 77(21):1913-20. PubMed ID: 22105948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
    Gertje EC; van Westen D; Panizo C; Mattsson-Carlgren N; Hansson O
    Neurology; 2021 Jan; 96(2):e193-e202. PubMed ID: 33046608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease.
    Inoue Y; Shue F; Bu G; Kanekiyo T
    Mol Neurodegener; 2023 Jul; 18(1):46. PubMed ID: 37434208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
    J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.